Progressive multifocal leukoencephalopathy in Zambia is caused by JC virus with prototype regulatory region

• Published in: Journal of neurovirology Vol. 25; no. 4; pp. 475 - 479
• Main Authors: Mubanga, Eugene, Patel, Atiyah, Siddiqi, Omar K., Hanson, Barbara A., Dang, Xin, Lakhi, Shabir, Mulundu, Gina, Bender, Noemi, Koralnik, Igor J.
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.08.2019
• Subjects: Biomedical and Life Sciences; Biomedicine; Immunology; Infectious Diseases; Neurology; Neurosciences; Virology; Zambia; JCV; Regulatory region; Progressive multifocal leukoencephalopathy
• ISSN: 1355-0284; 1538-2443; 1538-2443
• DOI: 10.1007/s13365-019-00746-x

There are only few documented cases of progressive multifocal leukoencephalopathy (PML) in Africa. Whether this is caused by a lack of JC virus (JCV) spread or alteration in the JCV genome is unknown. We characterized the clinical presentation, laboratory findings, and JCV regulatory region (RR) pattern of the first documented PML cases in Zambia as well as JCV seroprevalence among HIV + and HIV − Zambians. We identified PML patients with positive JCV DNA PCR in their cerebrospinal fluid (CSF) among subjects enrolled in an ongoing tuberculous meningitis study from 2014 to 2016 in Lusaka. JCV regulatory region was further characterized by duplex PCR in patients’ urine and CSF. Of 440 HIV + patients, 14 (3%) had detectable JCV DNA in their CSF (age 18–50; CD4 + T cells counts 15–155 × 10 6 /μl) vs 0/60 HIV − patients. The main clinical manifestations included altered mental status and impaired consciousness consistent with advanced PML. While prototype JCV was identified by duplex PCR assay in the CSF samples of all 14 PML patients, only archetype JCV was detected in their urine. All PML Zambian patients tested were seropositive for JCV compared to 46% in a control group of HIV + and HIV − Zambian patients without PML. PML occurs among HIV-infected individuals in Zambia and is caused by CNS infection with prototype JCV, while archetype JCV strains are present in their urine. JCV seroprevalence is comparable in Zambia and the USA, and PML should be included in the differential diagnosis of immunosuppressed individuals presenting with neurological dysfunction in Zambia.